The impact of DNMT3A/FLT3-ITD/NPM1 on patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Long Su
2018 Turkish Journal of Hematology  
Recently, Ardestani et al. [1] published their excellent findings in this journal. They found that DNMT3A mutations alone do not affect the clinical outcomes of acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), but when accompanied by FLT3-ITD mutations, the overall survival (OS) was significantly reduced and the relapse rate increased. NPM1 mutations had no impact on either relapse-free survival or OS, but there was a significant
more » ... was a significant difference between AML patients with and without NPM1 mutations for relapse [1]. Figure 3. Survival curves of acute myeloid leukemia patients according to DNMT3A/FLT3-ITD/NPM1 triple mutations: relapse free survival (left) and overall survival (right) (A=DNMT3A/FLT3-ITD/NPM1, B=others).
doi:10.4274/tjh.2018.0274 fatcat:cl5acr36wrhatossffe5vjqf6a